Daxor Cost Of Revenue vs Current Deferred Revenue Analysis

DXR Stock

USD 8.50 0.41 5.07%

Daxor financial indicator trend analysis is much more than just examining Daxor latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Daxor is a good investment. Please check the relationship between Daxor Cost Of Revenue and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Daxor. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Daxor Stock, please use our How to Invest in Daxor guide.

Cost Of Revenue vs Current Deferred Revenue

Cost Of Revenue vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Daxor Cost Of Revenue account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Daxor's Cost Of Revenue and Current Deferred Revenue is 0.15. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Daxor, assuming nothing else is changed. The correlation between historical values of Daxor's Cost Of Revenue and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Daxor are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Cost Of Revenue i.e., Daxor's Cost Of Revenue and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Daxor income statement and represents the costs associated with goods and services Daxor provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Daxor's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Daxor current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Daxor. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Daxor Stock, please use our How to Invest in Daxor guide.At this time, Daxor's Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 01/18/2025, Enterprise Value Over EBITDA is likely to grow to 129.58, while Selling General Administrative is likely to drop slightly above 335.8 K.

	2022	2023	2024	2025 (projected)
Research Development	14.65	0.01	0.0115	0.0109
Cost Of Revenue	1.1M	1.1M	1.0M	592.7K

Research Development Cost Of Revenue

Daxor fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock	Short Term Investments	Other Current Assets	Treasury Stock
Total Assets		0.63	0.8	0.26	0.66	0.47	-0.21	0.35	-0.93	0.74	-0.21	0.72	0.14	0.24	0.55	0.84	0.66	0.72	0.72	0.51	0.26	0.11	0.11	0.26	0.75	-0.01
Short Long Term Debt Total	0.63		0.29	-0.01	0.89	-0.13	0.07	0.43	-0.7	0.04	0.07	0.27	-0.01	0.85	0.42	0.76	0.24	0.26	0.26	0.02	-0.01	0.56	0.56	-0.17	0.39	-0.36
Total Stockholder Equity	0.8	0.29		0.39	0.41	0.79	-0.31	0.6	-0.81	0.67	-0.31	0.35	0.26	0.03	0.45	0.38	0.28	0.35	0.35	0.23	0.4	-0.08	-0.08	0.55	0.34	0.2
Property Plant And Equipment Net	0.26	-0.01	0.39		0.43	0.53	-0.96	0.51	-0.47	0.2	-0.96	0.03	-0.68	-0.04	-0.13	0.03	-0.16	0.04	0.04	-0.36	1.0	0.07	0.07	0.79	0.05	-0.58
Net Debt	0.66	0.89	0.41	0.43		0.14	-0.39	0.59	-0.83	0.12	-0.39	0.27	-0.29	0.74	0.27	0.7	0.15	0.26	0.26	-0.14	0.43	0.5	0.5	0.15	0.37	-0.6
Retained Earnings	0.47	-0.13	0.79	0.53	0.14		-0.56	0.34	-0.52	0.59	-0.56	0.29	0.12	-0.37	-0.02	0.1	0.19	0.31	0.3	0.17	0.53	-0.39	-0.39	0.61	0.22	0.12
Cash	-0.21	0.07	-0.31	-0.96	-0.39	-0.56		-0.34	0.42	-0.23	1.0	-0.13	0.63	0.14	0.25	-0.06	0.06	-0.15	-0.14	0.26	-0.96	0.04	0.04	-0.67	-0.13	0.59
Non Current Assets Total	0.35	0.43	0.6	0.51	0.59	0.34	-0.34		-0.58	-0.1	-0.34	-0.38	-0.17	0.52	0.25	0.0	-0.47	-0.37	-0.38	-0.55	0.51	0.31	0.31	0.52	-0.32	-0.22
Non Currrent Assets Other	-0.93	-0.7	-0.81	-0.47	-0.83	-0.52	0.42	-0.58		-0.55	0.42	-0.52	0.01	-0.39	-0.43	-0.75	-0.41	-0.52	-0.52	-0.19	-0.47	-0.23	-0.23	-0.33	-0.58	0.25
Other Assets	0.74	0.04	0.67	0.2	0.12	0.59	-0.23	-0.1	-0.55		-0.23	0.82	0.28	-0.34	0.46	0.56	0.79	0.82	0.82	0.76	0.21	-0.24	-0.24	0.35	0.76	0.24
Cash And Short Term Investments	-0.21	0.07	-0.31	-0.96	-0.39	-0.56	1.0	-0.34	0.42	-0.23		-0.13	0.63	0.14	0.25	-0.06	0.06	-0.15	-0.14	0.26	-0.96	0.04	0.04	-0.67	-0.13	0.59
Net Receivables	0.72	0.27	0.35	0.03	0.27	0.29	-0.13	-0.38	-0.52	0.82	-0.13		0.15	-0.18	0.28	0.83	0.98	1.0	1.0	0.84	0.03	-0.12	-0.12	-0.04	0.99	0.03
Common Stock Shares Outstanding	0.14	-0.01	0.26	-0.68	-0.29	0.12	0.63	-0.17	0.01	0.28	0.63	0.15		-0.11	0.33	0.08	0.28	0.15	0.16	0.46	-0.68	-0.19	-0.19	-0.43	0.11	0.72
Non Current Liabilities Total	0.24	0.85	0.03	-0.04	0.74	-0.37	0.14	0.52	-0.39	-0.34	0.14	-0.18	-0.11		0.22	0.37	-0.19	-0.19	-0.19	-0.35	-0.05	0.75	0.75	-0.18	-0.06	-0.37
Other Stockholder Equity	0.55	0.42	0.45	-0.13	0.27	-0.02	0.25	0.25	-0.43	0.46	0.25	0.28	0.33	0.22		0.43	0.31	0.27	0.27	0.3	-0.12	0.02	0.02	0.09	0.32	0.09
Total Liab	0.84	0.76	0.38	0.03	0.7	0.1	-0.06	0.0	-0.75	0.56	-0.06	0.83	0.08	0.37	0.43		0.79	0.82	0.82	0.56	0.03	0.26	0.26	-0.13	0.89	-0.22
Total Current Assets	0.66	0.24	0.28	-0.16	0.15	0.19	0.06	-0.47	-0.41	0.79	0.06	0.98	0.28	-0.19	0.31	0.79		0.98	0.98	0.91	-0.16	-0.13	-0.13	-0.17	0.96	0.16
Other Current Liab	0.72	0.26	0.35	0.04	0.26	0.31	-0.15	-0.37	-0.52	0.82	-0.15	1.0	0.15	-0.19	0.27	0.82	0.98		1.0	0.84	0.04	-0.12	-0.12	-0.03	0.98	0.03
Total Current Liabilities	0.72	0.26	0.35	0.04	0.26	0.3	-0.14	-0.38	-0.52	0.82	-0.14	1.0	0.16	-0.19	0.27	0.82	0.98	1.0		0.85	0.03	-0.13	-0.13	-0.04	0.98	0.04
Accounts Payable	0.51	0.02	0.23	-0.36	-0.14	0.17	0.26	-0.55	-0.19	0.76	0.26	0.84	0.46	-0.35	0.3	0.56	0.91	0.84	0.85		-0.35	-0.33	-0.33	-0.21	0.77	0.48
Property Plant And Equipment Gross	0.26	-0.01	0.4	1.0	0.43	0.53	-0.96	0.51	-0.47	0.21	-0.96	0.03	-0.68	-0.05	-0.12	0.03	-0.16	0.04	0.03	-0.35		0.07	0.07	0.8	0.05	-0.57
Common Stock Total Equity	0.11	0.56	-0.08	0.07	0.5	-0.39	0.04	0.31	-0.23	-0.24	0.04	-0.12	-0.19	0.75	0.02	0.26	-0.13	-0.12	-0.13	-0.33	0.07		1.0	-0.06	0.01	-0.36
Common Stock	0.11	0.56	-0.08	0.07	0.5	-0.39	0.04	0.31	-0.23	-0.24	0.04	-0.12	-0.19	0.75	0.02	0.26	-0.13	-0.12	-0.13	-0.33	0.07	1.0		-0.06	0.01	-0.36
Short Term Investments	0.26	-0.17	0.55	0.79	0.15	0.61	-0.67	0.52	-0.33	0.35	-0.67	-0.04	-0.43	-0.18	0.09	-0.13	-0.17	-0.03	-0.04	-0.21	0.8	-0.06	-0.06		-0.07	-0.15
Other Current Assets	0.75	0.39	0.34	0.05	0.37	0.22	-0.13	-0.32	-0.58	0.76	-0.13	0.99	0.11	-0.06	0.32	0.89	0.96	0.98	0.98	0.77	0.05	0.01	0.01	-0.07		-0.06
Treasury Stock	-0.01	-0.36	0.2	-0.58	-0.6	0.12	0.59	-0.22	0.25	0.24	0.59	0.03	0.72	-0.37	0.09	-0.22	0.16	0.03	0.04	0.48	-0.57	-0.36	-0.36	-0.15	-0.06

Click cells to compare fundamentals

Daxor Account Relationship Matchups

Daxor fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	16.6M	25.0M	30.3M	34.9M	40.1M	46.0M
Short Long Term Debt Total	170.7K	3.0M	1.2M	755.7K	869.0K	825.6K
Total Stockholder Equity	15.7M	21.2M	29.0M	34.0M	39.1M	31.3M
Net Debt	(447.1K)	2.3M	1.2M	755.7K	869.0K	825.6K
Retained Earnings	14.9M	19.6M	24.8M	25.1M	28.9M	18.0M
Non Current Assets Total	15.7M	24.2M	30.2M	34.8M	40.1M	42.1M
Non Currrent Assets Other	(15.7M)	(24.2M)	(30.2M)	(34.8M)	(31.4M)	(32.9M)
Other Assets	851.7K	733.8K	20.6K	34.9M	40.1M	26.2M
Net Receivables	29.3K	30.7K	17.2K	14.2K	16.3K	15.5K
Common Stock Shares Outstanding	3.9M	4.0M	4.1M	4.6M	4.2M	3.7M
Liabilities And Stockholders Equity	16.6M	25.0M	30.3M	34.9M	40.1M	46.0M
Non Current Liabilities Total	170.7K	3.0M	1.3M	755.7K	680.1K	646.1K
Other Stockholder Equity	(14.1M)	(18.1M)	(20.7M)	8.9M	8.0M	7.6M
Total Liab	877.7K	3.8M	1.3M	858.8K	987.6K	938.2K
Total Current Assets	29.3K	30.7K	17.2K	25.9K	29.8K	28.3K
Other Current Liab	(80K)	(87.4K)	(62.4K)	(103.1K)	(118.6K)	(112.6K)
Total Current Liabilities	80K	87.4K	62.4K	103.1K	118.6K	112.6K
Accounts Payable	80K	87.4K	62.4K	103.1K	92.8K	146.9K
Accumulated Other Comprehensive Income	14.9M	19.6M	24.8M	25.1M	28.9M	30.3M
Other Current Assets	851.7K	733.8K	20.6K	11.7K	13.4K	12.8K
Short Term Debt	4.5M	1.3M	627K	715.8K	823.2K	782.0K
Net Tangible Assets	12.8M	15.7M	21.2M	29.0M	26.1M	19.4M
Long Term Investments	15.7M	24.2M	30.2M	34.8M	40.1M	25.9M
Net Invested Capital	15.8M	24.2M	30.2M	34.8M	40.0M	24.3M

Pair Trading with Daxor

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daxor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daxor will appreciate offsetting losses from the drop in the long position's value.

Moving together with Daxor Stock

0.81

Cigna Corp

Pair Corr

Moving against Daxor Stock

0.72	ECOR	Electrocore LLC	Pair Corr
0.64	VVOS	Vivos Therapeutics	Pair Corr
0.6	EW	Edwards Lifesciences Corp Sell-off Trend	Pair Corr
0.52	EMBC	Embecta Corp	Pair Corr
0.46	OM	Outset Medical	Pair Corr

The ability to find closely correlated positions to Daxor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daxor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daxor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daxor to buy it.

The correlation of Daxor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daxor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daxor moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Daxor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Daxor Stock Analysis

When running Daxor's price analysis, check to measure Daxor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daxor is operating at the current time. Most of Daxor's value examination focuses on studying past and present price action to predict the probability of Daxor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daxor's price. Additionally, you may evaluate how the addition of Daxor to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC